Cambridge-Based Sequential Raises $3.5 Million
Sequential, a company specializing in advanced microbiome testing for personal care products, has successfully raised $3.5 million in its latest funding round. This round was led by Sparkfood, with additional participation from Corundum Systems Biology (CSB), Dermazone Holdings, SOSV, Scrum Ventures, and Innovate UK.
Founded by Albert Dashi and Oliver Worsley, who serve as Chief Scientific Officer and Chief Executive Officer respectively, Sequential aims to deliver actionable insights that enhance the efficacy of personal care products and build consumer trust.
Strategic Investors
The funding round was spearheaded by Sparkfood, a notable investor with a history of backing innovative biotech ventures. Alongside Sparkfood, other prominent investors such as CSB, Dermazone Holdings, SOSV, Scrum Ventures, and Innovate UK have shown their confidence in Sequential’s potential by contributing to this round.
Use of Funds
While specific plans for the newly acquired funds have not been detailed, the investment is expected to support Sequential’s efforts in advancing their microbiome testing capabilities. This could likely involve expanding their product offerings, enhancing research capabilities, or broadening their market presence in the personal care sector.
About Sequential
Operating out of Cambridge, England, Sequential is at the forefront of microbiome testing technology. The company’s services provide personal care brands with critical insights that can improve product performance and consumer satisfaction. By leveraging advanced testing methods, Sequential helps brands optimize their formulations based on scientific data.
Leadership Remarks
Albert Dashi, Co-Founder and CSO, and Oliver Worsley, Co-Founder and CEO, have been instrumental in driving the company's growth and technological advancements. Although no direct quotes from the founders were available, their leadership is pivotal in navigating Sequential through this promising phase of expansion.
This funding round marks a significant milestone for Sequential as it continues to innovate in the realm of personal care product development. With the backing of experienced investors, the company is well-positioned to further its mission of enhancing product efficacy through cutting-edge microbiome testing.